# Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

Study · id `cardio:ct-nct03285594` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03285594](<https://clinicaltrials.gov/study/NCT03285594>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03285594

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 571 participants.

## Technical summary

Registry record NCT03285594. Randomized; double masking; primary purpose treatment. Start 2017-09-15 (actual); primary completion 2019-09-17 (actual). Results posted on 2021-05-11.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 571 participants (enrolled count; ClinicalTrials.gov record NCT03285594, source copy `cardio:ctgov-nct03285594-2021-05-11`, retrieved 2026-10-26)
- Started: 2017-09-15 (actual) (ClinicalTrials.gov record NCT03285594, source copy `cardio:ctgov-nct03285594-2021-05-11`, retrieved 2026-10-26)
- Primary completion: 2019-09-17 (actual) (ClinicalTrials.gov record NCT03285594, source copy `cardio:ctgov-nct03285594-2021-05-11`, retrieved 2026-10-26)
- Completion: 2019-09-27 (actual) (ClinicalTrials.gov record NCT03285594, source copy `cardio:ctgov-nct03285594-2021-05-11`, retrieved 2026-10-26)
- Results first posted: 2021-05-11 (ClinicalTrials.gov record NCT03285594, source copy `cardio:ctgov-nct03285594-2021-05-11`, retrieved 2026-10-26)
- Countries: United States; Bulgaria; Canada; Czechia; France; Hungary; Slovakia; United Kingdom (ClinicalTrials.gov record NCT03285594, source copy `cardio:ctgov-nct03285594-2021-05-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03285594-2021-05-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
- Acronym: SOTA-INS
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Sotagliflozin
- Intervention (Drug): Insulin glargine (HOE901)
- Intervention (Drug): Placebo
- Intervention (Drug): Oral Antidiabetes Drugs (OADs)
- Lead sponsor: Lexicon Pharmaceuticals
- Lead sponsor class: INDUSTRY
- Collaborator: Sanofi
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Lexicon Pharmaceuticals (`cardio:org-lexicon-pharmaceuticals`)
- Registry lists this organization as a collaborator: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 4e05a69877c866e080be91349ec2fc7aa124d784fb8efe0627d816db5f133dbc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
